BNTX - BioNTech SE

-

$undefined

N/A

(N/A)

BioNTech SE NasdaqGS:BNTX BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Location: An der Goldgrube 12, Mainz, 55131, Germany | Website: https://www.biontech.de | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

9.215B

Cash

14.11B

Avg Qtr Burn

-63.93M

Short % of Float

5.74%

Insider Ownership

62.69%

Institutional Own.

22.26%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
COMIRNATY (BNT162b2) Details
COVID-19, Infectious disease

Approved

Quarterly sales

BNT323/DB-1303 Details
Cancer, Breast cancer

Phase 3

Data readout

Phase 3

Update

BNT323/DB-1303 Details
Cancer, HER2-expressing cancers, Endometrial cancer

Phase 3

Initiation

Phase 2

Data readout

BNT113 Details
Head and neck cancer, Human papillomavirus

Phase 2

Data readout

BNT116 +/- cemiplimab Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

Phase 2

Data readout

BNT316 (ONC-392) Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 2

Data readout

Autogene Cevumeran (BNT122) (w/ pembrolizumab) Details
Non-small cell lung carcinoma, Solid tumor/s, Bladder cancer, Melanoma

Phase 2

Interim update

BNT327/PM8002 Details
Cancer, Solid tumor/s, Cervical cancer, Platinum-resistant ovarian cancer

Phase 2

Update

Autogene cevumeran (BNT122) (RO7198457) Details
Solid tumor/s, Colorectal cancer

Phase 2

Update

BNT311/GEN1046 +/- pembrolizumab Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 2

Update

Phase 2

Update

BNT325 (DB-1305) Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s, Platinum-resistant ovarian cancer

Phase 1/2

Data readout

BNT166 Details
Vaccine, Smallpox

Phase 1/2

Data readout

BNT312/GEN1042 Details
Cancer, Solid tumor/s

Phase 1/2

Data readout

BNT324/DB-1311 Details
Solid tumor/s, Cancer

Phase 1/2

Data readout

BNT211 Details
Cancer, Solid tumor/s

Phase 1/2

Data readout

BNT323/DB-1303 Details
Cancer, Solid tumor/s, HER2-expressing cancers

Phase 1/2

Update

BNT167 Details
Vaccine, Shingles

Phase 1/2

Update

BNT327/PM8002 Details
Non-small cell lung carcinoma, Cancer, Lung cancer

Phase 1b

Update

BNT164 Details
Vaccine, Tuberculosis

Phase 1

Data readout

BNT116 +/- cemiplimab Details
Cancer, Non-small cell lung carcinoma, Solid tumor/s

Phase 1

Data readout

BNT326/YL202 Details
Cancer, HER2-expressing cancers, Breast cancer, Non-small cell lung carcinoma

Phase 1

Update

Phase 1

Update